{
    "subtypes": {
      "LUAD EGFR-mutated": {
        "description": "Lung adenocarcinoma with EGFR driver mutations",
        "therapy_levels": {
          "1": {
            "name": "Low Intensity Therapy",
            "description": "Conservative approach for low-risk disease",
            "recommendations": [
              {
                "therapy": "EGFR TKI monotherapy",
                "details": "Osimertinib, Gefitinib, or Erlotinib",
                "duration": "Until progression"
              },
              {
                "therapy": "Active surveillance",
                "details": "For asymptomatic, small nodules or ground glass opacities",
                "indication": "Elderly or frail patients"
              }
            ],
            "follow_up": "Every 3 months with imaging",
            "indications": [
              "Early-stage disease (I-II)",
              "Elderly or frail patients",
              "Significant comorbidities"
            ]
          },
          "2": {
            "name": "Standard Therapy",
            "description": "Balanced approach for intermediate-risk disease",
            "recommendations": [
              {
                "therapy": "EGFR TKI therapy",
                "details": "Osimertinib preferred for first-line",
                "duration": "Until progression"
              },
              {
                "therapy": "Consider adjuvant EGFR TKI",
                "details": "After surgical resection for early stage",
                "duration": "3 years"
              }
            ],
            "follow_up": "Every 2-3 months with imaging",
            "indications": [
              "Stage III-IV disease",
              "Good performance status",
              "Common EGFR mutations (exon 19 deletion, L858R)"
            ]
          },
          "3": {
            "name": "Intensified Therapy",
            "description": "More aggressive approach for high-risk disease",
            "recommendations": [
              {
                "therapy": "EGFR TKI + Anti-angiogenic",
                "details": "Osimertinib + Bevacizumab or Ramucirumab",
                "duration": "Until progression"
              },
              {
                "therapy": "Consider local therapy for oligoprogression",
                "details": "SBRT or surgical resection",
                "indication": "Limited sites of progression"
              }
            ],
            "follow_up": "Every 6-8 weeks with imaging",
            "indications": [
              "Brain metastases",
              "Uncommon EGFR mutations",
              "Bulky disease"
            ]
          },
          "4": {
            "name": "Maximum Intensity Therapy",
            "description": "Most aggressive approach for very high-risk disease",
            "recommendations": [
              {
                "therapy": "Combination therapy",
                "details": "EGFR TKI + chemotherapy",
                "regimen": "Osimertinib + platinum-pemetrexed"
              },
              {
                "therapy": "Clinical trial",
                "details": "Novel approaches for EGFR resistance",
                "examples": "EGFR/MET bispecific antibodies, 4th generation TKIs"
              }
            ],
            "follow_up": "Every 6 weeks with imaging",
            "indications": [
              "Resistance to earlier-line TKIs",
              "T790M or C797S mutations",
              "Rapid progression",
              "Multiple organ involvement"
            ]
          }
        }
      },
      "LUAD ALK-rearranged": {
        "description": "Lung adenocarcinoma with ALK gene rearrangements",
        "therapy_levels": {
          
        }
      },
      "LUAD KRAS-mutated": {
        "description": "Lung adenocarcinoma with KRAS mutations",
        "therapy_levels": {
          
        }
      },
      "LUSC": {
        "description": "Lung squamous cell carcinoma",
        "therapy_levels": {
          
        }
      }
    },
    "special_biomarkers": {
      "EGFR_mutation": {
        "clinical_significance": "Driver mutation and therapeutic target in NSCLC",
        "therapy_options": [
          {
            "name": "Osimertinib",
            "indication": "First-line for EGFR mut+ NSCLC, better for brain mets",
            "evidence_level": "Level 1A"
          },
          {
            "name": "Gefitinib/Erlotinib",
            "indication": "First-generation TKIs for EGFR mut+ NSCLC",
            "evidence_level": "Level 1A"
          }
        ]
      },
      "ALK_rearrangement": {
        "clinical_significance": "Driver alteration and therapeutic target in NSCLC",
        "therapy_options": [
          {
            "name": "Alectinib",
            "indication": "First-line for ALK+ NSCLC",
            "evidence_level": "Level 1A"
          },
          {
            "name": "Lorlatinib",
            "indication": "Later-line for ALK+ NSCLC with resistance",
            "evidence_level": "Level 1A"
          }
        ]
      },
      "KRAS_G12C_mutation": {
        "clinical_significance": "Targetable KRAS mutation subtype",
        "therapy_options": [
          {
            "name": "Sotorasib",
            "indication": "Approved for KRAS G12C+ NSCLC after prior therapy",
            "evidence_level": "Level 1A"
          }
        ]
      },
      "PD-L1_high": {
        "clinical_significance": "Predictive biomarker for immunotherapy response",
        "therapy_options": [
          {
            "name": "Pembrolizumab monotherapy",
            "indication": "First-line for NSCLC with PD-L1 â‰¥50%",
            "evidence_level": "Level 1A"
          }
        ]
      }
    },
    "therapy_levels": {
      "1": {
        "name": "Low Intensity Therapy",
        "description": "Conservative approach for low-risk disease or patients with comorbidities",
        "general_indications": [
          "Early-stage disease",
          "Elderly or frail patients", 
          "Significant comorbidities"
        ],
        "follow_up": "Every 3-4 months with imaging",
        "monitoring": "Low-dose CT scans, symptom monitoring"
      },
      "2": {
        "name": "Standard Therapy",
        "description": "Balanced approach for most patients with average risk disease",
        "general_indications": [
          "Locally advanced or metastatic disease",
          "Good performance status (ECOG 0-1)",
          "Standard molecular profile"
        ],
        "follow_up": "Every 2-3 months with imaging",
        "monitoring": "Regular CT scans, possible molecular testing for resistance"
      },
      "3": {
        "name": "Intensified Therapy",
        "description": "More aggressive approach for high-risk disease",
        "general_indications": [
          "Presence of brain metastases",
          "Uncommon or complex molecular alterations",
          "Limited progression on initial therapy"
        ],
        "follow_up": "Every 6-8 weeks with imaging",
        "monitoring": "Regular CT/MRI, molecular testing for resistance mechanisms"
      },
      "4": {
        "name": "Maximum Intensity Therapy",
        "description": "Most aggressive approach for very high-risk disease",
        "general_indications": [
          "Treatment resistance", 
          "Rapid progression",
          "Multiple lines of prior therapy",
          "Clinically aggressive disease"
        ],
        "follow_up": "Every 6 weeks with imaging",
        "monitoring": "Frequent CT/MRI, molecular testing, close symptom monitoring"
      }
    }
  }